Programme Monday, 26.10.2020 <\/strong><\/h3>\nStream 1: 10.30\u201311.00<\/span><\/strong><\/span><\/p>\nProf. Dr. Dr. h.c. Viola Vogel<\/strong>, Head of the Laboratory of Applied Mechanobiology, ETH Z\u00fcrich (CH)
\nNew <\/strong>N<\/strong>anotechnology <\/strong>D<\/strong>erived <\/strong>I<\/strong>nsights and <\/strong>A<\/strong>pproaches to <\/strong>F<\/strong>ight <\/strong>I<\/strong>nfection and <\/strong>I<\/strong>nflammation
\n<\/strong><\/span>The purpose of this virtual discussion is to ask how nanotechnology tools could help to address major challenges in Medicine. This includes discussing how novel nanotech probes and imaging technologies are helping us to rewrite textbooks how pathogens invade hosts, and vice versa, how hosts are fighting infections, and equally important to define novel approaches to fight infection and inflammation more effectively, and hopefully one day with less side effects.<\/p>\n <\/p>\n
Stream 2: 11.00 \u201311.30<\/span><\/strong><\/span><\/p>\nProf. Dr. Janos Szebeni, <\/strong>professor of immunology and nanomedicine at Semmelweis U, also CEO\/CSO of Seroscience Ltd, an immune toxicology\u00a0CRO in Budapest (H)
\nImmune Side Effects of Nanomedicine
\n<\/strong><\/span>JS, will address questions on hypersensitivity reactions to and immunogenicity of nanoparticles. These adverse immune effects represent a risk for altered pharmacokinetics and\/or life-threatening infusion reactions, which are potentially incompatible with the clinical use of nanomedicines and contrast\u00a0agents. Over >20 years of experience in this field and the capability to serve the nanomedicine field with in vitro and in vivo assays predicting these adverse effects, Prof Szebeni is on the frontline\u00a0in solving these problems.<\/p>\n <\/p>\n
Stream 3: 12.00 \u2013 12.30<\/span><\/span> <\/strong><\/p>\nProf. Dr. Rudolf Zentel, <\/strong>Institute of Organic Chemistry University of Mainz (D)
\nNanoparticles in the Biological Context: Protein Corona Formation
\n<\/strong><\/span>Rudolf Zentel from the University of Mainz will elucidate: A recent paper demonstrated that the formation of a protein corona is not a general property of all types of nanosized objects. In fact, it varies between a massive aggregation of plasma proteins onto the nanoparticle down to traces (e.g. a few proteins per 10 nanoparticles), which can only be determined by mass spectrometry in comparison to appropriate negative controls. The difference is related to the surface morphology of the particles (the difference between a strongly hydrated \/ swollen shell vs a sharp “hard” surface). This topic is rarely discussed. Thus it should be considered that \u201cnot all nanoparticles are alike\u201d!<\/p>\n\u00a0<\/strong><\/p>\nStream 1: 13.00 \u2013 13.30<\/span><\/strong><\/span><\/p>\nDr. Dr. Josbert Metselaar, PharmD, PhD<\/strong>, Department of Experimental Molecular Imaging, RWTH Aachen, University Clinic, Aachen (D) and CEO Enceladus, Pharmaceuticals, Naarden (N)
\nClinical and Commercial Feasibility of Nanomedicine Drug Product Development
\n<\/strong><\/span>Bart Metselaar (RWTH Aachen University) would like to open the floor of this debate lounge for a discussion about clinical and commercial feasibility of nanomedicine drug product development for inflammation. Inflammatory and autoimmune disease is a busy field to operate in with many new products ranging from small-molecular kinase inhibitors to monoclonal antibody biologics. How much room is there for new nanomedicine products? What inflammatory disease should we develop our products for? Should we answer this question from an unmet medical need point of view (top-down) or from a scientific rationale (bottom-up) point of view? All thoughts, comments and view are welcome, please share and join!<\/p>\n\u00a0<\/strong><\/p>\nStream 2: <\/span>14.00 \u2013 14.30 <\/span><\/strong><\/p>\nProf. Dr. med Patrick Hunziker, <\/strong>Leader of the Intensive Care Clinic of the University Hospital Basel, President of the International Society for Nanomedicine and CSO of the European Foundation for Clinical nanomedicine
\nNanomedicine at Clinic
\n<\/strong><\/span>Patrick Hunziker has 12 years of experience in nanomedicine at the clinic. As a clinician he shows the hurdles and
\nthe benefits of using nanotechnology in medicine. To what extent are today nanomedicines used and what are the future\u00a0perspectves?<\/p>\nFurther topics to be proposed by the delegates <\/strong>[\/vc_wp_text][\/vc_column][\/vc_row][vc_row][vc_column][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"[vc_row gap=”35″ equal_height=”yes” css=”.vc_custom_1600096338092{background-color: #f18800 !important;}”][vc_column width=”1\/2″][vc_custom_heading text=”Zoom Debate lounge” font_container=”tag:h1|text_align:left|color:%23ffffff” google_fonts=”font_family:PT%20Sans%3Aregular%2Citalic%2C700%2C700italic|font_style:700%20bold%20regular%3A700%3Anormal”][\/vc_column][vc_column width=”1\/2″][vc_custom_heading text=”” font_container=”tag:h2|text_align:left|color:%23ffffff” google_fonts=”font_family:PT%20Sans%3Aregular%2Citalic%2C700%2C700italic|font_style:400%20regular%3A400%3Anormal”][\/vc_column][\/vc_row][vc_row gap=”35″][vc_column css=”.vc_custom_1600096546505{padding-right: 50px !important;padding-left: 50px !important;background-color: #fcfcfc !important;border-radius: 5px !important;}”][vc_wp_text] Zoom Debate Lounge in Streams 1, 2 and 3 Dear Delegates As an interactive addition to live streaming the CLINAM Foundation has installed a chat zoom room in each…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"open","ping_status":"open","template":"","meta":{"footnotes":""},"class_list":["post-393","page","type-page","status-publish","hentry","description-off"],"_links":{"self":[{"href":"https:\/\/conference.clinam.org\/index.php\/wp-json\/wp\/v2\/pages\/393"}],"collection":[{"href":"https:\/\/conference.clinam.org\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/conference.clinam.org\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/conference.clinam.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/conference.clinam.org\/index.php\/wp-json\/wp\/v2\/comments?post=393"}],"version-history":[{"count":14,"href":"https:\/\/conference.clinam.org\/index.php\/wp-json\/wp\/v2\/pages\/393\/revisions"}],"predecessor-version":[{"id":965,"href":"https:\/\/conference.clinam.org\/index.php\/wp-json\/wp\/v2\/pages\/393\/revisions\/965"}],"wp:attachment":[{"href":"https:\/\/conference.clinam.org\/index.php\/wp-json\/wp\/v2\/media?parent=393"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}